US: Gender Differences in Respiratory Care

Activity Title

Gender Differences in Respiratory Care

Program Goals

Pulmonary conditions such as asthma, COPD, and sleep-disordered breathing affect women differently than men. In some diseases, presentation differs, such as the higher frequency of exacerbations experienced by women with chronic obstructive pulmonary disease or greater prevalence of pulmonary hypertension in women. Evidence also suggests that women may be less likely to be diagnosed than men for certain lung conditions such as COPD.

The purpose of this program is to review the current understanding of the biological, behavioral, and clinical implications of female sex/gender on lung and sleep health disease, and to propose clinical approaches for achieving better health outcomes through more precise management of female patients with lung disease. The activity will inform physicians and advanced practitioners about the importance of considering sex and gender when evaluating patients with pulmonary disease, with sex being a biological construct and gender encompassing not just biology but also social and environmental factors that may influence disease presentation, diagnosis, progression and treatment.

Target Audience

The educational design of this activity addresses the needs of everyone in the healthcare facilities specifically; pulmonologists, critical care specialists, thoracic surgeons, radiologists, internal medicine and primary care physicians, physician assistants, advanced practice nurses, and nurse practitioners.

Learning Objectives

After completion of this activity participants will be able to:

Analyze pulmonary disease burden among women.
Describe how gender may influence pulmonary disease presentation and progression.
Recognize clinical implications of gender differences in pulmonary disease.
Explain differences in risk for pulmonary vascular disease between men and women.
Describe sex-based differences in treatment responses in pulmonary arterial hypertension.
Discuss resiliency to disease progression in women with established pulmonary arterial hypertension.

Faculty

MeiLan K. Han, MD MS
Henry Sewall Endowed Professor of Medicine
Chief, Pulmonary and Critical Care
University of Michigan
Division of Pulmonary and Critical Care Medicine
Ann Arbor, MI

Anna R. Hemnes, MD
Associate Professor
Division of Allergy, Pulmonary and Critical Care Medicine
Vanderbilt University Medical Center

Educational Activity Agenda

Front Matter & Registration (5 minutes)
Educational Presentation (74 minutes)
Post Test, Evaluation & Certificate delivery (11 minutes)
Total Activity (90 minutes)

Release and Expiration Dates

Release Date: Febuary 2, 2025
Expiration Date: Febuary 2, 2027

Disclosure of Conflicts of Interests

Dane Garvin Ltd. (DGL) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided and/or hosted by DGL are required to disclose all financial relationships with any ineligible company within the past 24 months to DGL. All financial relationships reported are identified as relevant and mitigated by DGL and any/all accreditation providers in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by DGL and AARC to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

Faculty Disclosures

The faculty have the following relevant financial relationships with ineligible companies:

MeiLan K. Han, MD MS

Consulting Fee (e.g., Advisory Board): AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Altesa Biopharma, Amgen, Roche, Medtronic
Contracted Research (Principal Investigators must provide information, even if received by the institution): Sanofi, Novartis, Nuvaira, Sunovion, Gala Therapeutics, AstraZeneca, Boehringer Ingelheim, Biodesix
Honoraria: Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medwiz
Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Meissa Vaccines, Altesa Biopharma
Other (describe): Writing Support: GSK, BI, AZ, Novartis

Anne R. Hemnes. MD

Consulting fee: Janssen, Bayer, United Therapeutics, GossamerBio, Merck, Tenax Therapeutics
Contracted Research: NIH
Stock Shareholder: Tenax Therapeutics

Planners and Managers

The planners and managers have the following relevant financial relationships with ineligible companies:

Gail A. Varcelotti, RRT FAARC

Nothing to disclose

Credit Designation - AARC

This Non-traditional program has been approved for 1.5 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care; 9425 N. MacArthur Boulevard, Suite 100, Irving TX 75063 Course #193817000

How to Obtain AARC / CRCE Credit

Attendees are expected to review all academic materials before attempting to apply for credit. Successful completion of this activity will lead to the issuance of a certificate for 1.5 contact hour of CRCE approved continuing education.

To receive credit, please follow these steps:

Complete the online registration (registration is free).
Review all of the academic materials provided.
Click on the CRCE link to apply for credit.
Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate.
Qualified applicants will be provided with an online (printable) CRCE certificate based on their attendance and satisfactory completion of this academic activity.

Click here to view the web conference

Fee Information

There is no fee for this educational activity.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Dane Garvin Ltd. (DGL) and/or accreditation providers for this educational activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Policy on Privacy and Confidentiality

Dane Garvin Ltd. (DGL) and MEDtalks protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. DGL and/or MEDtalks will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency.

DGL and MEDtalks maintain physical, electronic and procedural safeguards that comply with US federal regulations and European General Data Protection Regulation (GDPR) to guard your nonpublic personal information.

Medium Used

This program has been made available online.
“Gender Differences in Respiratory Care”

System Requirements

To view this educational activity you will need a web browser with Javascript and either Flash or HTML5 enabled. Nearly all modern web browsers will work.

Commercial Support Statement

This online Resource Center is supported by an Educational Grant from Philips Respironics, Inc.

Copyright

Copyright © MEDtalks & Dane Garvin, Ltd. All Rights Reserved. Permission for accreditation use granted to the American Association for Respiratory Care (AARC). Web interface provided by Dane Garvin Ltd.


	Activity Title Click here to register for this event Gender Differences in Respiratory Care Program Goals Pulmonary conditions such as asthma, COPD, and sleep-disordered breathing affect women differently than men. In some diseases, presentation differs, such as the higher frequency of exacerbations experienced by women with chronic obstructive pulmonary disease or greater prevalence of pulmonary hypertension in women. Evidence also suggests that women may be less likely to be diagnosed than men for certain lung conditions such as COPD. The purpose of this program is to review the current understanding of the biological, behavioral, and clinical implications of female sex/gender on lung and sleep health disease, and to propose clinical approaches for achieving better health outcomes through more precise management of female patients with lung disease. The activity will inform physicians and advanced practitioners about the importance of considering sex and gender when evaluating patients with pulmonary disease, with sex being a biological construct and gender encompassing not just biology but also social and environmental factors that may influence disease presentation, diagnosis, progression and treatment. Target Audience The educational design of this activity addresses the needs of everyone in the healthcare facilities specifically; pulmonologists, critical care specialists, thoracic surgeons, radiologists, internal medicine and primary care physicians, physician assistants, advanced practice nurses, and nurse practitioners. Learning Objectives After completion of this activity participants will be able to: Analyze pulmonary disease burden among women. Describe how gender may influence pulmonary disease presentation and progression. Recognize clinical implications of gender differences in pulmonary disease. Explain differences in risk for pulmonary vascular disease between men and women. Describe sex-based differences in treatment responses in pulmonary arterial hypertension. Discuss resiliency to disease progression in women with established pulmonary arterial hypertension. Faculty MeiLan K. Han, MD MS Henry Sewall Endowed Professor of Medicine Chief, Pulmonary and Critical Care University of Michigan Division of Pulmonary and Critical Care Medicine Ann Arbor, MI Anna R. Hemnes, MD Associate Professor Division of Allergy, Pulmonary and Critical Care Medicine Vanderbilt University Medical Center Educational Activity Agenda Front Matter & Registration (5 minutes) Educational Presentation (74 minutes) Post Test, Evaluation & Certificate delivery (11 minutes) Total Activity (90 minutes) Release and Expiration Dates Release Date: Febuary 2, 2025 Expiration Date: Febuary 2, 2027 Disclosure of Conflicts of Interests Dane Garvin Ltd. (DGL) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided and/or hosted by DGL are required to disclose all financial relationships with any ineligible company within the past 24 months to DGL. All financial relationships reported are identified as relevant and mitigated by DGL and any/all accreditation providers in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by DGL and AARC to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. Faculty Disclosures The *faculty* have the following relevant financial relationships with ineligible companies: MeiLan K. Han, MD MS Consulting Fee (e.g., Advisory Board): AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pulmonx, Teva, Verona, Merck, Mylan, Sanofi, DevPro, Aerogen, Polarian, Regeneron, Altesa Biopharma, Amgen, Roche, Medtronic Contracted Research (Principal Investigators must provide information, even if received by the institution): Sanofi, Novartis, Nuvaira, Sunovion, Gala Therapeutics, AstraZeneca, Boehringer Ingelheim, Biodesix Honoraria: Cipla, Chiesi, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Medwiz Stock Option Holder (Individual stocks/Stock options; diversified mutual funds do not need to be disclosed): Meissa Vaccines, Altesa Biopharma Other (describe): Writing Support: GSK, BI, AZ, Novartis Anne R. Hemnes. MD Consulting fee: Janssen, Bayer, United Therapeutics, GossamerBio, Merck, Tenax Therapeutics Contracted Research: NIH Stock Shareholder: Tenax Therapeutics Planners and Managers The *planners and managers* have the following relevant financial relationships with ineligible companies: Gail A. Varcelotti, RRT FAARC Nothing to disclose Credit Designation - AARC This Non-traditional program has been approved for 1.5 contact hour Continuing Respiratory Care Education (CRCE) credit by the American Association for Respiratory Care; 9425 N. MacArthur Boulevard, Suite 100, Irving TX 75063 Course #193817000 How to Obtain AARC / CRCE Credit Attendees are expected to review all academic materials before attempting to apply for credit. Successful completion of this activity will lead to the issuance of a certificate for 1.5 contact hour of CRCE approved continuing education. To receive credit, please follow these steps: Complete the online registration (registration is free). Review all of the academic materials provided. Click on the CRCE link to apply for credit. Complete the online test and/or evaluation. Participants must receive a test score of at least 70% and answer all evaluation questions to receive a certificate. Qualified applicants will be provided with an online (printable) CRCE certificate based on their attendance and satisfactory completion of this academic activity. Click here to view the web conference Fee Information There is no fee for this educational activity. Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Dane Garvin Ltd. (DGL) and/or accreditation providers for this educational activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Disclaimer Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Policy on Privacy and Confidentiality Dane Garvin Ltd. (DGL) and MEDtalks protect the privacy of personal and other information regarding participants, educational partners, and joint sponsors. DGL and/or MEDtalks will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the appropriate accrediting agency. DGL and MEDtalks maintain physical, electronic and procedural safeguards that comply with US federal regulations and European General Data Protection Regulation (GDPR) to guard your nonpublic personal information. Medium Used This program has been made available online. “Gender Differences in Respiratory Care” System Requirements To view this educational activity you will need a web browser with Javascript and either Flash or HTML5 enabled. Nearly all modern web browsers will work. Commercial Support Statement This online Resource Center is supported by an Educational Grant from Philips Respironics, Inc. Copyright Copyright © MEDtalks & Dane Garvin, Ltd. All Rights Reserved. Permission for accreditation use granted to the American Association for Respiratory Care (AARC). Web interface provided by Dane Garvin Ltd.